CEL-SCI Corporation operates as a clinical-stage biotechnology company focused on research and development of novel immunotherapies, most notably its lead investigational therapy for head and neck cancer. Determining whether the stock is a favorable investment depends entirely on an investor's appetite for high-risk biotechnology speculation, as late-stage drug developers face binary outcomes tied directly to clinical efficacy data and regulatory approval processes. Because the company typically incurs continuous net losses prior to commercial product sales, prospective shareholders must carefully analyze cash reserves, funding dilution risks, and independent analyst assessments before committing capital.